Citations

Showing 10 of 108094 citations.

Bone changes in the vascularised fibular graft
Boer, HH de, Wood, M. B., Hh, de Boer

Mayo Clinic

The Journal of Bone and Joint Surgery. British volume | February 21, 2018 | Volume: 71-B | Issue: 3 | Pages: 374-378

10.1302/0301-620x.71b3.2722923 | PMID 2722923 Get It

We report a retrospective review of 62 consecutive patients who had a vascularised fibular transfer to reconstruct a large skeletal defect. We were particularly interested in the bone dynamics of the vascularised graft, since fractures occurred in 25% of the cases at an average time of eight months after surgery. Hypertrophy was more common when the limb was mechanically loaded; it was enhanced where the graft was not bypassed by internal fixation. The length of the graft and the use of additional bone graft material had no influence on the incidence of stress fracture or on hypertrophy. We conclude that a vascularised graft should be protected against fatigue fracture during the first year, and that a gradual increase in mechanical loading will enhance remodelling and hypertrophy.
Discovery of a cause of vein of Galen malformations
Meschia, James F.

Mayo Clinic

Brain | February 20, 2018 | Volume: 141 | Issue: 4 | Pages: 936-938

10.1093/brain/awy066 | PMID 29596666 Get It

Determinants of hematology-oncology trainees' postfellowship career pathways with a focus on nonmalignant hematology
Marshall, Ariela L. , Jenkins, Sarah M. , Gitlin, Scott D., Mıkhael, Joseph , Marshall, Ariela

Mayo Clinic

Blood Advances | February 20, 2018 | Volume: 2 | Issue: 4 | Pages: 361-369

10.1182/bloodadvances.2017013722 | PMID 29463548 Get It

Key Points Hematology-oncology fellowship graduates spend a relatively small proportion of their time practicing nonmalignant hematology. Factors that may increase interest in nonmalignant hematology include better access to mentors and improved opportunities for career growth.
Longitudinal Changes in Serum Glucose Levels are Associated with Metabolic Changes in Alzheimer’s Disease Related Brain Regions
Burns, Christine , Kaszniak, Alfred W., Lee, Wendy , Bandy, Daniel, Caselli, Richard J. , Reiman, Eric M. , Chen, Kewei

Mayo Clinic

Journal of Alzheimer’s Disease | February 20, 2018 | Volume: 62 | Issue: 2 | Pages: 833-840

10.3233/jad-170767 | PMID 29480176 Get It

Background: The association between longitudinal changes in serum glucose level and longitudinal changes in [ 18 F] Fluorodeoxyglucose-PET (FDG PET) measurements of Alzheimer’s disease (AD) risk are unknown. Objective: To investigate whether variation in serum glucose levels across time are associated with changes in FDG PET measurements of cerebral metabolic rate for glucose (rCMRgl) in brain regions preferentially affected by Alzheimer’s disease (AD). Methods: Participants are a subset of a prospective cohort study investigating FDG PET, apolipoprotein E (APOE) ɛ4, and risk for AD which includes data from baseline, interim, and follow up visits over 4.4±1.0-years. An automated brain-mapping algorithm was utilized to characterize and compare associations between longitudinal changes in serum glucose levels and longitudinal changes in rCMRgl. Results: This study included 80 adults aged 61.5±5 years, including 38 carriers and 42 non-carriers of the APOE ɛ4 allele. Longitudinal increases in serum glucose levels were associated with longitudinal CMRgl decline in the vicinity of parietotemporal, precuneus/posterior cingulate, and prefrontal brain regions preferentially affected by AD ( p < 0.05, corrected for multiple comparisons). Findings remained significant when controlled for APOE ɛ4 status and baseline and advancing age. Conclusions: Additional studies are needed to clarify and confirm the relationship between longitudinal changes in peripheral glucose and FDG PET measurements of AD risk. Future findings will set the stage on the use of FDG PET in the evaluation of possible interventions that target risk factors for the development of AD.
Cumulative experience and long term follow-up of pentostatin-based chemoimmunotherapy trials for patients with chronic lymphocytic leukemia
LaPlant, Betsy, Pettinger, Adam, Call, Timothy G. , Leis, José F., Conte, Michael, Bowen, Deborah A., LaPlant, Betsy R, Pettinger, Adam M., Conte, Michael J, Kay, Neil E. , Ding, Wei , Parikh, Sameer A. , Shanafelt, Tait D.

Mayo Clinic

Expert Review of Hematology | February 20, 2018 | Volume: 11 | Issue: 4 | Pages: 337-349

10.1080/17474086.2018.1442716 | PMID 29460654 Get It

Novel Targeted Therapy Strategies for Biliary Tract Cancers and Hepatocellular Carcinoma
DeLeon, Thomas, Ahn, Daniel H. , Anastasiadis, Panos Z. , Arora, Mansi , Ramanathan, Ramesh K., Aqel, Bashar , Vasmatzis, George , Truty, Mark J. , Öklü, Rahmi , Bekaii‐Saab, Tanios , DeLeon, Thomas T, Bogenberger, James M. , Oklu, Rahmi , Bekaii-Saab, Tanios S , Aqel, Bashar A. , Borad, Mitesh J.

Mayo Clinic

Future Oncology | February 20, 2018 | Volume: 14 | Issue: 6 | Pages: 553-566

10.2217/fon-2017-0451 | PMID 29460642 Get It

LRRK2 p.Ile1371Val Mutation in a Case with Neuropathologically Confirmed Multi-System Atrophy
Lee, Kelsey , Nguyen, Khanh-Dung H., Liu, Mei , Zafar, Faria , Saetern, Jimmy, Flierl, Adrian , Tetrud, James W., Langston, J. William, Schüle, Birgitt , Sun, Chao , Dickson, Dennis W.

Mayo Clinic

Journal of Parkinson’s Disease | February 20, 2018 | Volume: 8 | Issue: 1 | Pages: 93-100

10.3233/jpd-171237 | PMID 29480226 Get It

Background: Mutations in the leucine rich repeat kinase 2 ( LRRK2) gene are among the most common genetic causes of Lewy body Parkinson’s disease (PD). However, LRRK2 mutations can also lead to a variety of pathological phenotypes other than typical PD, including relatively pure nigrostriatal cell loss without alpha-synuclein-positive Lewy bodies or Lewy neurites, progressive supranuclear palsy (PSP), and multiple system atrophy (MSA). The mechanisms behind this remarkable pleomorphic pathology are currently unclear. Objective: To genetically and pathologically characterize a case with a LRRK2, p.Ile1371Val rare variant and pathologically proven MSA. Methods: From the brain donation program at the Parkinson’s Institute and Clinical Center, we selected 26 brains with family history and a with clinicopathological diagnosis of PD ( n = 20), MSA ( n = 4), or PSP ( n = 2). We performed neuropathological evaluation, including alpha-synuclein and tau immunohistochemistry and sequenced 188 genes that have been reported as causative for or associated with neurodegenerative diseases. Results: We identified a known LRRK2, p.Ile1371Val genetic variant in a case with clinically diagnosed and pathologically proven MSA. Neuropathology revealed that the olivopontocerebellar system was more affected than the striatonigral system. Conclusions: Our data suggest that genetic variants in the LRRK2 gene can present clinically and neuropathologically as MSA. One other LRRK2 genetic variant ( LRRK2, p.Ile2020Thr) has been reported with a neuropathological diagnosis of MSA. Interestingly, the LRRK2 variant ( LRRK2, p.Ile1371Val) identified here has been reported previously in a postmortem case with Lewy body PD. Future studies are critical to discover the mechanisms leading to different neurodegenerative trajectories both in neuronal and glial cell populations.
Dietary Fiber Treatment Corrects the Composition of Gut Microbiota, Promotes SCFA Production, and Suppresses Colon Carcinogenesis
Bishehsari, Faraz , Preite, Nailliw Z. , Tunçil, Yunus E. , Shaikh, Maliha, Rossi, Marco , Wilber, Sherry , Green, Stefan J. , Hamaker, Bruce R. , Khazaie, Khashayarsha , Voigt, Robin M. , Forsyth, Christopher B. , Preite, Nailliw Z , Tuncil, Yunus E , Green, Stefan J , Engen, Phillip A. , Naqib, Ankur D , Keshavarzian, Ali

Mayo Clinic

Genes | February 20, 2018 | Volume: 9 | Issue: 2 | Pages: 102

10.3390/genes9020102 | PMID 29462896 Get It

Epidemiological studies propose a protective role for dietary fiber in colon cancer (CRC). One possible mechanism of fiber is its fermentation property in the gut and ability to change microbiota composition and function. Here, we investigate the role of a dietary fiber mixture in polyposis and elucidate potential mechanisms using TS4Cre × cAPCl°x468 mice. Stool microbiota profiling was performed, while functional prediction was done using PICRUSt. Stool short-chain fatty acid (SCFA) metabolites were measured. Histone acetylation and expression of SCFA butyrate receptor were assessed. We found that SCFA-producing bacteria were lower in the polyposis mice, suggesting a decline in the fermentation product of dietary fibers with polyposis. Next, a high fiber diet was given to polyposis mice, which significantly increased SCFA-producing bacteria as well as SCFA levels. This was associated with an increase in SCFA butyrate receptor and a significant decrease in polyposis. In conclusion, we found polyposis to be associated with dysbiotic microbiota characterized by a decline in SCFA-producing bacteria, which was targetable by high fiber treatment, leading to an increase in SCFA levels and amelioration of polyposis. The prebiotic activity of fiber, promoting beneficial bacteria, could be the key mechanism for the protective effects of fiber on colon carcinogenesis. SCFA-promoting fermentable fibers are a promising dietary intervention to prevent CRC.
Advanced EUS Guided Tissue Acquisition Methods for Pancreatic Cancer
Kandel, Pujan , Wallace, Michael B. , Wallace, Michael B

Mayo Clinic

Cancers | February 20, 2018 | Volume: 10 | Issue: 2 | Pages: 54

10.3390/cancers10020054 | PMID 29463004 Get It

Pancreas cancer is a lethal cancer as the majority patients are diagnosed at an advanced incurable stage. Despite improvements in diagnostic modalities and management strategies, including surgery and chemotherapies, the outcome of pancreas cancer remains poor. Endoscopic ultrasound (EUS) is an important imaging tool for pancreas cancer. For decades, resected pancreas cancer and other cancer specimens have been used to identify tissue biomarkers or genomics for precision therapy; however, only 20% of patients undergo surgery, and thus, this framework is not useful for unresectable pancreas cancer. With advancements in needle technologies, tumor specimens can be obtained at the time of tissue diagnosis. Tumor tissue can be used for development of personalized cancer treatment, such as performing whole exome sequencing and global genomic profiling of pancreas cancer, development of tissue biomarkers, and targeted mutational assays for precise chemotherapy treatment. In this review, we discuss the recent advances in tissue acquisition of pancreas cancer.
Treatment-Free Remission After Second-Line Nilotinib Treatment in Patients With Chronic Myeloid Leukemia in Chronic Phase
Mahon, François-Xavier, Boquimpani, Carla , Kim, Dong‐Wook , Benyamini, Noam , Clementino, Nelma Cristina D., Shuvaev, Vasily , Paz, Raquel de , Moiraghi, Beatriz, Nicolini, Franck E. , Dengler, Jolanta, Sacha, Tomasz , Takahashi, Naoto , Fellague-Chebra, Rafik, Acharya, Sandip, Wong, Stephane, Jin, Yu , Hughes, Timothy P. , Mahon, François Xavier, Ailawadhi, Sikander , Lipton, Jeffrey Howard , Turkina, Anna

Mayo Clinic

Annals of Internal Medicine | February 19, 2018 | Volume: 168 | Issue: 7 | Pages: 461-470

10.7326/m17-1094 | PMID 29459949 Get It